313 related articles for article (PubMed ID: 35347591)
41. Development of New Cancer Treatment by Identifying and Focusing the Genetic Mutations or Altered Expression in Gynecologic Cancers.
Tang YH; Lin CY; Lai CH
Genes (Basel); 2021 Oct; 12(10):. PubMed ID: 34680987
[TBL] [Abstract][Full Text] [Related]
42. Advances in ovarian cancer therapy.
Cortez AJ; Tudrej P; Kujawa KA; Lisowska KM
Cancer Chemother Pharmacol; 2018 Jan; 81(1):17-38. PubMed ID: 29249039
[TBL] [Abstract][Full Text] [Related]
43. New and Novel Therapies for Gynecologic Cancers.
Richardson DL
Semin Oncol Nurs; 2019 Apr; 35(2):217-219. PubMed ID: 30876683
[TBL] [Abstract][Full Text] [Related]
44. Poly(ADP-Ribose) polymerase 1: a therapeutic hope in gynecologic cancers.
Rajawat J; Shukla N; Mishra DP
Front Biosci (Schol Ed); 2017 Jun; 9(3):343-356. PubMed ID: 28410123
[TBL] [Abstract][Full Text] [Related]
45. Integrating antibody drug conjugates in the management of gynecologic cancers.
Chelariu-Raicu A; Mahner S; Moore KN; Lorusso D; Coleman RL
Int J Gynecol Cancer; 2023 Mar; 33(3):420-429. PubMed ID: 36878560
[TBL] [Abstract][Full Text] [Related]
46. Current and emerging treatment options in the management of advanced ovarian cancer.
Rodriguez-Freixinos V; Mackay HJ; Karakasis K; Oza AM
Expert Opin Pharmacother; 2016 Jun; 17(8):1063-76. PubMed ID: 26918413
[TBL] [Abstract][Full Text] [Related]
47. Personalized Medicine in Gynecologic Cancer: Fact or Fiction?
Corey L; Valente A; Wade K
Surg Oncol Clin N Am; 2020 Jan; 29(1):105-113. PubMed ID: 31757307
[TBL] [Abstract][Full Text] [Related]
48. Management of the toxicities of common targeted therapeutics for gynecologic cancers.
Gunderson CC; Matulonis U; Moore KN
Gynecol Oncol; 2018 Mar; 148(3):591-600. PubMed ID: 29395304
[TBL] [Abstract][Full Text] [Related]
49. Epithelial ovarian cancer: Evolution of management in the era of precision medicine.
Lheureux S; Braunstein M; Oza AM
CA Cancer J Clin; 2019 Jul; 69(4):280-304. PubMed ID: 31099893
[TBL] [Abstract][Full Text] [Related]
50. Strategic Combination Therapies for Ovarian Cancer.
Li X; Ng ASN; Mak VCY; Chan KKL; Cheung ANY; Cheung LWT
Curr Cancer Drug Targets; 2020; 20(8):573-585. PubMed ID: 32392113
[TBL] [Abstract][Full Text] [Related]
51. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
Zheng F; Zhang Y; Chen S; Weng X; Rao Y; Fang H
Biomed Pharmacother; 2020 Mar; 123():109661. PubMed ID: 31931287
[TBL] [Abstract][Full Text] [Related]
52. Molecular profiling of gynecologic cancers for treatment and management of disease - demonstrating clinical significance using the AMP/ASCO/CAP guidelines for interpretation and reporting of somatic variants.
Nie Q; Omerza G; Chandok H; Prego M; Hsiao MC; Meyers B; Hesse A; Uvalic J; Soucy M; Bergeron D; Peracchio M; Burns S; Kelly K; Rowe S; Rueter J; Reddi HV
Cancer Genet; 2020 Apr; 242():25-34. PubMed ID: 31992506
[TBL] [Abstract][Full Text] [Related]
53. Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies.
Vaidya AP; Parnes AD; Seiden MV
Curr Treat Options Oncol; 2005 Mar; 6(2):103-14. PubMed ID: 15717992
[TBL] [Abstract][Full Text] [Related]
54. Immuno-oncology for Gynecologic Malignancies.
How J; Patel A; Jazaeri A
Adv Exp Med Biol; 2020; 1244():149-182. PubMed ID: 32301014
[TBL] [Abstract][Full Text] [Related]
55. Major clinical research advances in gynecologic cancer in 2014.
Suh DH; Lee KH; Kim K; Kang S; Kim JW
J Gynecol Oncol; 2015 Apr; 26(2):156-67. PubMed ID: 25872896
[TBL] [Abstract][Full Text] [Related]
56. Systematic inhibitor selectivity between PARP1 and PARP2 enzymes: Molecular implications for ovarian cancer personalized therapy.
Zuo X; Zhao H; Li D
J Mol Recognit; 2021 Jul; 34(7):e2891. PubMed ID: 33684965
[TBL] [Abstract][Full Text] [Related]
57. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
[TBL] [Abstract][Full Text] [Related]
58. Asian Society of Gynecologic Oncology International Workshop 2014.
Park JY; Ngan HY; Park W; Cao Z; Wu X; Ju W; Chung HH; Chang SJ; Park SY; Ryu SY; Kim JH; Cho CH; Lee KH; Lee JW; Kumarasamy S; Kim JW; Wilailak S; Kim BG; Kim DY; Konishi I; Lee JK; Wang KL; Nam JH
J Gynecol Oncol; 2015 Jan; 26(1):68-74. PubMed ID: 25609163
[TBL] [Abstract][Full Text] [Related]
59. Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine.
Zamarin D; Jazaeri AA
Gynecol Oncol; 2016 Apr; 141(1):86-94. PubMed ID: 27016233
[TBL] [Abstract][Full Text] [Related]
60. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
Chung C; Lee R
J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
